Corinne Danan - Veracyte Senior President

VCYT Stock  USD 21.03  0.11  0.53%   

President

Corinne Danan is Senior President of Veracyte
Address 6000 Shoreline Court, South San Francisco, CA, United States, 94080
Phone650 243 6300
Webhttps://www.veracyte.com

Veracyte Management Efficiency

Return On Tangible Assets is likely to drop to -0.23 in 2024. Return On Capital Employed is likely to drop to -0.01 in 2024. At this time, Veracyte's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 1.2 B in 2024, whereas Non Current Liabilities Total is likely to drop slightly above 19.6 M in 2024. Veracyte's management efficiency ratios could be used to measure how well Veracyte manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 12.63 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Veracyte has a current ratio of 4.01, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Veracyte until it has trouble settling it off, either with new capital or with free cash flow. So, Veracyte's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Veracyte sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Veracyte to invest in growth at high rates of return. When we think about Veracyte's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 7 records

PRESIDENT Age

Robert WongCytokinetics
56
Stephen BetzCrinetics Pharmaceuticals
58
Mark SmytheProtagonist Therapeutics
59
Ashok BhandariProtagonist Therapeutics
60
Hui LiuMerus BV
57
Suneel GuptaProtagonist Therapeutics
65
Ching JawCytokinetics
61
The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis Prosigna Breast Cancer Assay for breast cancer diagnosis Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis and Immunoscore Colon Cancer test for colon cancer diagnosis. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California. Veracyte operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 761 people. Veracyte (VCYT) is traded on NASDAQ Exchange in USA. It is located in 6000 Shoreline Court, South San Francisco, CA, United States, 94080 and employs 815 people. Veracyte is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Veracyte Leadership Team

Elected by the shareholders, the Veracyte's board of directors comprises two types of representatives: Veracyte inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Veracyte. The board's role is to monitor Veracyte's management team and ensure that shareholders' interests are well served. Veracyte's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Veracyte's outside directors are responsible for providing unbiased perspectives on the board's policies.
Robert Brainin, Executive Officer
John Leite, Chief Business
Annie McGuire, Sr Counsel
Tracy Morris, VP Communications
Corinne Danan, Senior President
Tina Nova, Director
Bonnie Anderson, Co-Founder, CEO and President Director and Member of Non-Management Equity Award Committee
Rebecca Chambers, Executive CFO
Jonathan Wygant, VP Officer
Phillip MD, Chief Officer
Beverly CPA, VP Controller
Karen Possemato, Communications Marketing
Giulia Kennedy, Chief Scientific Officer, Chief Medical Officer
Steven French, Senior Officer
Marc Stapley, CEO Director

Veracyte Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Veracyte a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Veracyte is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Veracyte Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Veracyte Stock. Highlighted below are key reports to facilitate an investment decision about Veracyte Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Veracyte. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing.
For more information on how to buy Veracyte Stock please use our How to Invest in Veracyte guide.
You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.

Complementary Tools for Veracyte Stock analysis

When running Veracyte's price analysis, check to measure Veracyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veracyte is operating at the current time. Most of Veracyte's value examination focuses on studying past and present price action to predict the probability of Veracyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veracyte's price. Additionally, you may evaluate how the addition of Veracyte to your portfolios can decrease your overall portfolio volatility.
Commodity Directory
Find actively traded commodities issued by global exchanges
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Fundamental Analysis
View fundamental data based on most recent published financial statements
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Is Veracyte's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Veracyte. If investors know Veracyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Veracyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.02)
Revenue Per Share
4.97
Quarterly Revenue Growth
0.223
Return On Assets
(0.01)
Return On Equity
(0.07)
The market value of Veracyte is measured differently than its book value, which is the value of Veracyte that is recorded on the company's balance sheet. Investors also form their own opinion of Veracyte's value that differs from its market value or its book value, called intrinsic value, which is Veracyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Veracyte's market value can be influenced by many factors that don't directly affect Veracyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Veracyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Veracyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Veracyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.